Nauck MA, Petrie JR, Sesti G et al (2016) A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes
Water Dipropylene Glycol Glycerin Butylene Glycol Niacinamide 1,2-Hexanediol Cetyl Ethylhexanoate Panthenol Allantoin Xylitol Centella Asiatica Leaf Extract Lactobacillus Ferment Lysate Lactococcus Ferment Lysate Bifida Ferment Lysate Caprylyl Glycol Sorbitan Laurate Hydrogenated Lecithin Hydrolyzed Hyaluronic Acid Tocopherol Asiaticoside Madecassic Acid Asiatic Acid Acetyl Dipeptide-1 Cetyl Ester Acetyl Hexapeptide-1 Palmitoyl Tripeptide-5 Beta-Glucan Ceramide NP Acetyl Octapeptide-3 hydrogenated Vegetable Oil Behenyl Alcohol Polyglyceryl-3 Methylglucose Distearate Arginine Carbomer Adenosine Hydroxyethylcellulose Ethylhexylglycerin Disodium EDTA
The hypothalamic-pituitary-gonadal axis responds positively to certain peptides that stimulate natural hormone production
The study reveals that the SLC25A39 transporter, which imports glutathione into mitochondria, is essential for cancer spread, and elevated SLC25A39 expression correlates with poorer survival outcomes in breast cancer patients, suggesting potential therapeutic targeting opportunities
Clinical trial extension data shows that people who discontinue treatment typically regain about two-thirds of their lost weight within one year
Both are expected to deliver top-line results around the middle of 2026
